Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Back to Familial Amyotrophic Lateral Sclerosis

Familial Amyotrophic Lateral Sclerosis — NIH Grants & Funding

Active and recent NIH-funded research on Familial Amyotrophic Lateral Sclerosis. Data from NIH RePORTER, last 36 months.

MONDO:0005144

Looking for specific grants? The Recent Research tab lets you search and filter by topic.

Funding Landscape

Familial Amyotrophic Lateral Sclerosis has a robust NIH research funding landscape with 43 funded grants and $52.3M in total funding over the period.

43funded grants from NIH

Portfolio: $36.4MCumulative: $52.3M27 active16 completed48 PIs30 institutions

3 new grants started in the last 12 months.

By Research Theme

Basic Science

Gene/Cell Therapy

Translational

Clinical

Biomarker / Dx

Funding by Fiscal Year

NIH fiscal year (Oct–Sep)

$6.8M

FY22

$9.6M

FY23

$8.7M

FY24

$26.3M

FY25

$920K

FY26

By Funding Mechanism

R01

RF1

R21

F31

K99

R00

Funding Gap Analysis

Cross-referencing NIH grants against published research and clinical trials to identify funding-evidence gaps for Familial Amyotrophic Lateral Sclerosis. Strongest funded area: Basic Science. Largest gap: Epidemiology / Natural History.

Clinical ResearchFunded, Few Publications

3 funded grants in Clinical Research but only 1 related publication found for familial amyotrophic lateral sclerosis. This may indicate early-stage research that hasn't yet produced published results.

Biomarker / DiagnosticsFunded, Few Publications

2 funded grants in Biomarker / Diagnostics but only 2 related publications found for familial amyotrophic lateral sclerosis. This may indicate early-stage research that hasn't yet produced published results.

Epidemiology / Natural HistoryPublished, Not NIH-Funded

6 publications in Case Report / Case Series but no NIH-funded grants found in Epidemiology / Natural History for familial amyotrophic lateral sclerosis. Existing research activity suggests this may be a viable area for grant applications.

Epidemiology / Natural HistoryPublished, Not NIH-Funded

8 publications in Epidemiology / Natural History but no NIH-funded grants found in Epidemiology / Natural History for familial amyotrophic lateral sclerosis. Existing research activity suggests this may be a viable area for grant applications.

Adjacent Research(18 grants)

These grants mention Familial Amyotrophic Lateral Sclerosis as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.

Other(18)

OtherR01Completed

Identification of TDP-43 modifiers through single-cell transcriptional and epigenomic dissection of ALS and FTLD-MND

Belzil, Veronique et al.·UNIVERSITY OF PITTSBURGH AT PITTSBURGH·PITTSBURGH, PA

$1,752,943 (FY2025)

NIH RePORTER

OtherR01Completed

In vivo modelling and therapy development for stathmin-2 loss in TDP-43 proteinopathies

Cleveland, Don et al.·MASSACHUSETTS GENERAL HOSPITAL·BOSTON, MA

$824,437 (FY2025)

NIH RePORTER

OtherR01Active

Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Lagier-Tourenne, Clotilde et al.·MASSACHUSETTS GENERAL HOSPITAL·BOSTON, MA

$682,793 (FY2026)

NIH RePORTER

OtherR01Active

Molecular Basis of Pathogenic Cascades in ALS/FTD Initiated from C9orf72 Hexanucleotide Repeat Expansion

Wang, Jiou·JOHNS HOPKINS UNIVERSITY·BALTIMORE, MD

$607,907 (FY2025)

NIH RePORTER

OtherR01Completed

Role of Ataxin-2 polyglutamine expansion on TDP-43 transport and post-transcriptional RNA regulation in neurons

Gopal, Pallavi·YALE UNIVERSITY·NEW HAVEN, CT

$418,527 (FY2025)

NIH RePORTER

OtherR33Active

Human-iPSC derived neuromuscular junctions as a model for neuromuscular diseases.

Miranda, Helen·CASE WESTERN RESERVE UNIVERSITY·CLEVELAND, OH

$390,007 (FY2025)

NIH RePORTER

OtherR00Active

Precision Base Editing for the Treatment of Motor Neuron Diseases

Arbab, Mandana·BOSTON CHILDREN'S HOSPITAL·BOSTON, MA

$249,000 (FY2026)

NIH RePORTER

OtherR21Completed

Peptide Nucleic Acid (PNA) Oligomers for Targeted Disruption of Biomolecular Condensates in ALS/FTD

ARMITAGE, Bruce et al.·CARNEGIE-MELLON UNIVERSITY·PITTSBURGH, PA

$232,953 (FY2025)

NIH RePORTER

OtherR42Completed

Mitofusin Agonists to Treat Neurodegenerative Disease

Dorn, Gerald et al.·MITOCHONDRIA IN MOTION, INC.·SAINT LOUIS, MO

$986,168 (FY2023)

NIH RePORTER

OtherR21Completed

Analysis of pathogenic mosaic mutations in human Amyotrophic Lateral Sclerosis nervous system

Lodato, Michael·UNIV OF MASSACHUSETTS MED SCH WORCESTER·WORCESTER, MA

$460,625 (FY2022)

NIH RePORTER

NIH Grants & Funding for Familial Amyotrophic Lateral Sclerosis | Kisho | Kisho

Kisho

Familial Amyotrophic Lateral Sclerosis — NIH Grants & Funding

Funding Landscape

By Research Theme

Funding by Fiscal Year

By Funding Mechanism

Funding Gap Analysis

Adjacent Research(18 grants)

Other(18)

Identification of TDP-43 modifiers through single-cell transcriptional and epigenomic dissection of ALS and FTLD-MND

In vivo modelling and therapy development for stathmin-2 loss in TDP-43 proteinopathies

Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Molecular Basis of Pathogenic Cascades in ALS/FTD Initiated from C9orf72 Hexanucleotide Repeat Expansion

Role of Ataxin-2 polyglutamine expansion on TDP-43 transport and post-transcriptional RNA regulation in neurons

Human-iPSC derived neuromuscular junctions as a model for neuromuscular diseases.

Precision Base Editing for the Treatment of Motor Neuron Diseases

Peptide Nucleic Acid (PNA) Oligomers for Targeted Disruption of Biomolecular Condensates in ALS/FTD

Mitofusin Agonists to Treat Neurodegenerative Disease

Analysis of pathogenic mosaic mutations in human Amyotrophic Lateral Sclerosis nervous system

Top Funded Institutions

Top Principal Investigators